Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034

Fineline Cube Oct 18, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...

Company Deals R&D

Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development

Fineline Cube Oct 18, 2023

German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...

Company Medical Device

Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Oct 18, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Drug

BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC

Fineline Cube Oct 18, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...

Company Deals

Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications

Fineline Cube Oct 18, 2023

Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision...

Company Deals

Hong Kong WinHealth Pharma Enters Strategic Partnership with Nippon Shinyaku for Irsogladine

Fineline Cube Oct 18, 2023

Hong Kong-based WinHealth Pharma Group Ltd has announced a strategic partnership with Nippon Shinyaku Co...

Company Deals

Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies

Fineline Cube Oct 18, 2023

Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...

Company

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Fineline Cube Oct 18, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...

Company Deals

Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection

Fineline Cube Oct 18, 2023

China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...

Company Deals

Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology

Fineline Cube Oct 18, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced...

Company Drug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Fineline Cube Oct 18, 2023

BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...

Company Drug

Mabwell to Present Promising Clinical Data at 2023 ESMO Congress

Fineline Cube Oct 18, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...

Company Deals

Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development

Fineline Cube Oct 18, 2023

Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in...

Company Deals

SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group

Fineline Cube Oct 18, 2023

China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals...

Company Digital

Baidu Launches Interactive AI Medication Instructions Service at Baidu World 2023

Fineline Cube Oct 18, 2023

Robin Li, CEO of China-based internet services giant Baidu, unveiled an innovative interactive AI medication...

Company Deals

Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone

Fineline Cube Oct 17, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...

Company Deals

Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment

Fineline Cube Oct 17, 2023

China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...

Company Drug

Asieris Pharma Launches Generic Votrient for Renal Cell Carcinoma in China

Fineline Cube Oct 17, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176),...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for Follicular Lymphoma Treatment

Fineline Cube Oct 17, 2023

China-based biotechnology leader BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the receipt of...

Company Deals

EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall

Fineline Cube Oct 17, 2023

Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall...

Posts pagination

1 … 453 454 455 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.